Biomarkers of Central Nervous System Involvement in Pome Disease
Title: BiomarkersA measurable sign in the body that helps track disease progression or treatment response. of Central Nervous System Involvement in Pompe DiseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup that damages muscles and can affect breathing and, in some cases, the heart.: New Learnings
Date: Thursday, September 24, 2026
Time: 10 a.m. CT / 11 a.m. ET
Speaker:
Kristen Hagarty-Waite, PhD, RDN, LDN
Summary:
Central nervous system (CNS) manifestations persist in patients with Pompe disease, despite enzymeA protein that helps the body carry out chemical reactions. replacement therapy, as current formulations cannot cross the blood brain barrier. Plasma glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) have emerged as biomarkers to monitor CNS involvement in Pompe disease, particularly for those with the infantile-onset phenotype. In this presentation, we will share our learnings, so far, regarding biomarkers of CNS involvement.
Reports of Nexviazyme Shipment Delays
Pompe Alliance, Marshall’s Mountain, Grant’s Giants, Pompe Warrior Foundation, Ryan Colburn of the Pompe Community, and the AMDA are working together to help patients obtain clear and timely information regarding reports of NexviazymeA newer enzyme replacement therapy designed to improve delivery of the enzyme to muscle cells. shipment and release delays.
At this time, the delays being reported to our organizations involve some shipments of Nexviazyme. We have not received confirmation that LumizymeA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of the GAA enzyme. is currently affected, but patients using either treatment may wish to verify their upcoming shipment.
This appears to be a product-release and distribution timing issue — not evidence of a safety or quality problem with medication that has already been released. Patients should not panic or make treatment changes without speaking with their prescribing medical team.
In June 2026, the FDA issued a warning letter following a January inspection of a Sanofi facility in Waterford, Ireland. Sanofi has publicly stated that products released from the facility meet established quality and safety specifications. The FDA warning letter does not specifically identify Nexviazyme or Lumizyme as affected products, and we cannot independently confirm the precise cause of every current shipment delay.
Vaccines and Pompe Disease: What to Know This Immunization Awareness Month
Every August, National Immunization Awareness Month (NIAM) puts a spotlight on one of the most effective tools we have to protect our health — vaccines. For the Pompe disease community, that message carries extra weight. Respiratory muscle weaknessA loss of strength that can affect movement, posture, and sometimes breathing. and impaired cough...
What Do Your Pompe Test Results Really Mean?
Title: What Do Your Pompe Test Results Really Mean? The Evolution of Pompe Diagnostics: Past, Present, and Future
Date: Thursday, August 20, 2026
Time: 1 p.m. CT / 2 p.m. ET
Speaker:
Deeksha Bali, PhD, FACMG
Summary:
This webinar examines Pompe disease diagnosis in the newborn screening era, drawing on lessons learned since implementation and the growing challenge of novel variants identified each year. It highlights the role of CRIM testing, GAA enzyme and mutationA change in a gene that can affect how it works. analysis, and urine Hex4 biomarker testing in achieving early, accurate diagnosis. The talk underscores an urgent need for a validated, disease-specific functional assay to characterize variants of unknown significance and support their reclassification, benefiting newly diagnosed patients. It also points to the promise of understanding Pompe disease’s molecular mechanisms to predict disease onset and progression and guide treatment decisions, an unmet need for patients identified through newborn screening.
The ADA at 36: What the Law Did, and What Only We Can Do
This month marks the 36th anniversary since the Americans with Disabilities Act (ADAProteins made by the immune system that may recognize enzyme replacement therapy as foreign and reduce its effectiveness.) was signed into law by President George H.W. Bush. At its core, the civil rights law was enacted to help prevent discrimination that folks with disabilities may face. It is meant to...
A Heartfelt Thank You to the Krueger Family
The Acid Maltase Deficiency Association is deeply grateful to the Krueger family for their remarkable and generous donation to our organization. Their gift is a powerful testament to their compassion for all those affected by Pompe disease and their commitment to...
Mental Health for Pompe Disease: The Importance of Being Understood
Title: Mental Health for Pompe Disease: The Importance of Being Understood
Date: Thursday, May 14, 2026
Speakers:
Heather Shorten
Nadia Bodkin, Pharm. D., MS
JC Muyl
Summary:
Living with Pompe disease means navigating far more than the physical realities of a complex, progressive condition. The emotional and psychological toll, including the uncertainty, the isolation, and the challenge of finding care that truly sees the whole person, is a dimension of this journey that is too often left unaddressed. This webinar brings together three advocates at the forefront of mental health and rare disease: Heather Shorten of Pompe Alliance, Nadia Bodkin of the Rare Advocacy Movement, and JC Muyl of Mental Health For Rare.
Drawing on community research and lived experience, our presenters will explore the unique emotional challenges tied to living with Pompe disease, why feeling understood matters so deeply, and what meaningful mental health support can look like for this community. Whether you are a patient, caregiver, healthcare provider, or advocate, this is an opportunity to be part of an important and long-overdue conversation about whole-person care in the Pompe disease community.
Move How You Can, Rest All You Need
Hey, all! Lucas Garrett, here. As we head into April, I wanted to take a minute to jot down a few ideas on staying healthy — physically and mentally. As many in the Pompe community may already be keenly aware, well-regulated habits of getting quality sleep, eating...
Immune Responses to AAV Gene Therapy
Title: Immune ResponsesThe body's natural defense system reacting to substances it sees as foreign, including treatments like enzyme replacement therapy or gene therapy. to AAVA harmless virus commonly used as a delivery system in gene therapy to carry healthy genes into cells. Gene TherapyA developing treatment that aims to fix, replace, or add genetic instructions.: Challenges and Emerging Solutions
Date: Thursday, April 23, 2026
Time: 12 p.m. CST / 1 p.m. EST
Speaker:
Abigail Benkert, MD
Summary:
Immune responses to AAV gene therapy remain a major barrier to its access and effectiveness. This talk will highlight key immune challenges and emerging strategies to overcome them, including antibody-cleaving enzymes and novel capsids designed to evade pre-existing immunity.
Honoring Advocacy: Celebrating Tiffany House and the RareVoice Awards
This week is Rare Disease Week, with events and activities taking place worldwide to bring awareness to rare diseases and honor the community. One such event is "Rare Disease Week on Capitol Hill," where Tiffany House is being featured as a RareVoice Awardee for State...
Tiffany House Receives RareVoice Award for State Advocacy
We are honored to share this moment recognizing Tiffany House as a recipient of the RareVoice Award for State Advocacy. The award is presented by the EveryLife Foundation For Rare Diseases.This award is given to advocates whose voices have helped shape meaningful...
2026 PCMA Pull for Pompe Fundraiser
The AMDA is excited to announce that the 15th Annual PCMA's Pull for Pompe fundraiser will take place on Saturday, May 2, 2026, from 8 a.m. to 2 p.m. CST at the National Shooting Complex in San Antonio, Texas! The Pull for Pompe clay shooting event is designed for all...
Making Sense of Research Studies and Registries
Title: Making sense of research studies and registries
Date: Thursday, February 19, 2026
Time: 7 PM CST / 8 PM EST
Speakers:
Karmen Trzupek
Ryan Colburn
Summary:
Have you heard about research studies and patient registries for Pompe disease? These studies are a critical tool in capturing the patient experience, which improves disease understanding, management, and treatment options.
Join this session to learn about the different types of research studies and patient registries for Pompe disease. What are the differences between them? How is the data shared and used? We’ll cover what you may want to consider when choosing to participate, cover a few of the historical registries that have contributed to progress in Pompe, and share an innovative patient led registry, Progress4Pompe, where patients own their data and choose how to share it.
With Gratitude: Honoring Our 2025 Donors
The Acid Maltase Deficiency Association (AMDA) is deeply grateful to the individuals, families, and organizations who contributed in 2025. Your generosity makes it possible for us to fund research and promote public awareness of Acid Maltase Deficiency, also known as Pompe disease.
New Year’s Resolutions and Hobbies
Are New Year’s resolutions already starting to feel heavy? Lucas explores why we put so much pressure on ourselves, and why breaking a resolution can spiral into guilt. His gentler reset is simple: pivot to a hobby, and if it does not bring you joy, you can stop without feeling bad about it. He also points to research linking hobby engagement with mental health and well-being.
Grief Happens in Rare Disease: Let’s Talk About it Already
Title: Grief Happens in Rare Disease: Let’s Talk About it Already
Date: Thursday, January 15, 2026
Time: 1 PM CST / 2 PM EST
Speaker:
Lisa Keefauver, MSW
Webinar Overview:
Given 100% of us experience loss, multiple times in our lives, means that when we work with humans, we’re working with grievers. That’s why our grief-illiterate culture is deeply problematic, causing so much unnecessary suffering. Based on her professional wisdom as a narrative-therapy trained social worker and her personal insights as a widow and cancer survivor, Keefauver combines metaphor, science, storytelling and humor to help audiences more fully understand the expansiveness and pervasiveness of both the sources and impact of grief in our work and personal lives.
Burnout, Creativity, and Rest
AMDA’s Lucas Garrett shares a thoughtful reflection on burnout and creativity — exploring how stepping back to rest can reignite inspiration and help restore a sense of balance, both in art and everyday life.
Tiffany House and Maryze Schoneveld van der Linde Honored at Sanofi’s Global Rare Impact Awards
Sanofi’s inaugural Global Rare Impact Awards recognized three pioneers in rare disease advocacy, including the AMDA’s late president Tiffany House and IPA board member Maryze Schoneveld van der Linde.
Morgan’s Story: When Hope Met Hurricane Katrina
Editor's NoteIn the early years of Pompe research, access to enzyme replacement therapy (ERT)A treatment that replaces the missing enzyme through IV infusion. was extremely limited. Long before FDA approval, a handful of families, physicians, and researchers worked tirelessly to secure treatment for patients diagnosed with Pompe...
Check Back Soon for Upcoming Webinars
We don’t have a webinar scheduled at the moment, but more exciting sessions are on the way! Check back soon for details, or sign up for our newsletter to be notified when new webinars are announced.
